

Press Release – For immediate release

## **BIOLIDICS TO COLLABORATE WITH A\*STAR'S GENOME INSTITUTE OF SINGAPORE TO DEVELOP NEW LIQUID BIOPSY TEST FOR THE MONITORING OF BREAST CANCER RECURRENCE**

- **The recurrence of breast cancer has been the leading cause of death for breast cancer survivors**
- **Combining the technology capabilities of both parties, this collaboration aims to co-develop a new and innovative liquid biopsy test, using the merits of CTCs and other circulating biomarkers, to predict the risk of breast cancer relapse**
- **Breast cancer is currently the most common type of cancer in women and with the rising incidence of breast cancer, the global cancer diagnostic market for breast cancer may surpass US\$2 billion in revenue by 2022<sup>1</sup>**

**Singapore, 10 September 2019 – Biolidics Limited (“Biolidics” or the “Company”),** a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce that it has entered into an agreement with Agency for Science, Technology and Research’s (A\*STAR ) Genome Institute of Singapore (GIS) for the collaboration and development of a new and innovative liquid biopsy test in the field of circulating tumour cells (CTCs) for the assessment of minimal residual disease (MRD) and predicting the risk of relapse in women who had breast cancer.

Researchers from GIS have previously identified a set of biomarkers, which identify breast cancer patients with higher likelihood of breast cancer relapse within five years.

Separate studies in the US independently report that the surveillance of CTCs presence in blood from early stage breast cancer women post-surgery allows identification of those at a significant higher risk of relapses<sup>2</sup>.

With its novel, patented technology, Biolidics’ ClearCell® FX1 System can perform liquid biopsies to test for the presence of cancer cells (specifically CTCs) in blood samples, hence the collaboration between Biolidics and GIS aims to co-develop a new and innovative liquid biopsy test to predict the risk of breast cancer relapse among breast cancer survivors.

**Mr. Ivan Lew (廖光品), Executive Director and CEO of Biolidics, said:** *“Driven by our bold ambitions and technology capabilities, we want to create a truly next-generation liquid biopsy platform in cancer diagnostics that can detect various forms of cancers at an early stage, thereby leading to lower healthcare costs and better clinical outcomes for patients.*

1. *Hospimedica International* - <https://www.hospimedica.com/business/articles/294777636/global-breast-cancer-diagnostics-market-to-surpass-usd-2-billion-by-2022.html>

2. *National Center for Biotechnology Information (NCBI)* - <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385891/?report=classic>

*With this collaboration with GIS, we can potentially develop an accurate and affordable liquid biopsy test to monitor and predict breast cancer recurrences, thereby enabling medication intervention to prevent a relapse.*

*Commercially, it opens up new opportunities for both of our technologies in the global cancer diagnostics market.”*

**Professor Patrick Tan, Executive Director of GIS said:** *“Breast Cancer is among one of the most common cancers in Singapore<sup>1</sup> and such tests help us to identify those patients at risk of early relapse, allowing for the best chance of treatment. We are excited to enter into this collaboration with Biolidics as it highlights the importance of research, and how it can be translated into outcomes that will improve the quality of life for patients.”*

- END -

## **About Biolidics Limited**

(Bloomberg Code: BLD: Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 System, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples so that further analysis may be performed on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA (formerly CFDA) Class I registration (for the MGI EasyCell System).

For additional information, please visit [www.biolidics.com](http://www.biolidics.com).

***Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.***

---

Media & Investor Contacts:



Mr. Alex TAN

Mobile: +65 9451 5252

Email: [alex.tan@8prasia.com](mailto:alex.tan@8prasia.com)

*This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*